Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia

Urology

Volumn 58, Issue 6 SUPPL. 1, 2001, Pages 25-32

  Barry, Michael J ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE; BLADDER NECK STENOSIS; CLINICAL FEATURE; CONFERENCE PAPER; CONTINENCE; DISEASE SEVERITY; HISTOLOGY; HUMAN; MALE; MEASUREMENT; MORBIDITY; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SEXUAL FUNCTION; SYMPTOM; TIME; URETHRA; URINARY TRACT INFECTION; URINARY TRACT OBSTRUCTION; URINE RETENTION;

AGED; HEALTH STATUS INDICATORS; HUMANS; MALE; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SEX; SEX FACTORS; URETHRAL OBSTRUCTION; URINATION DISORDERS;

EID: 0035652778     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01300-0     Document Type: Conference Paper

References (42)

1. Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia
2. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia
3. Correlation of American Urological Association Symptom Index with obstructive and nonobstructive prostatism
4. A comparison of different indices of responsiveness
5. New words for old; lower urinary tract symptoms for 'prostatism.'
6. The American Urological Association symptom index for benign prostatic hyperplasia
7. Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes
8. Measuring disease-specific health status in men with benign prostatic hyperplasia
9. Patient reactions to a program designed to facilitate patient participation in decisions for benign prostatic hyperplasia
10. Benign prostatic hyperplasia specific health status measures in clinical research; how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?
11. Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical management of prostate disease
12. International Prostate Symptom Score and quality of life assessment versus urodynamic parameters in men with benign prostatic hyperplasia symptoms
13. The relationship of the International Prostate Symptom Score and objective parameters for diagnosing bladder outlet obstruction, I; when statistics fail
14. Distinction between symptoms of voiding and filling in benign prostatic hyperplasia; findings from the Health Professionals Follow-up Study
15. Filling and voiding symptoms in the American Urological Association Symptom Index; the value of their distinction in a Veterans Affairs randomized trial of medical therapy in men with a clinical diagnosis of benign prostatic hyperplasia
16. The American Urological Association symptom index; does mode of administration affect its psychometric properties?
17. The influence of patient education level on the International Prostatic Symptom Score
18. The International Prostate Symptom Score; physician versus self-administration in the quantification of symptomatology
19. Does the mode of questionnaire administration affect the reporting of urinary symptoms?
20. An assessment of the comprehension of the American Urological Association Symptom Index
21. Measurement of overall and disease-specific health status; does the order of questionnaires make a difference?
22. Effect of scrambling on the short-term reliability of the American Urological Association Symptom Index
23. Effect of age, educational status, ethnicity and geographic location on prostate symptom scores
24. Influence of sociodemographic and health status variables on the American Urological Association symptom scores in patients with lower urinary tract symptoms
25. Committee 6; measuring the symptoms and health impact of benign prostatic hyperplasia and its treatments
26. Results of an epidemiological survey using a modified American Urological Association symptom index for benign prostatic hyperplasia in France
27. Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia evaluated with the DAN-PSS-1 score system
28. Comparison of the Danish Prostatic Symptom Score with the International Prostatic Symptom Score, the Madsen-Iversen and Boyarsky symptom indexes
29. Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia
30. A patient weighted symptom score system in the evaluation of uncomplicated benign prostatic hyperplasia
31. Scoring the short form ICSmaleSF questionnaire
32. The ICS-'BPH' Study; the psychometric validity and reliability of the ICSmale questionnaire
33. Relationships between lower urinary tract symptoms and bladder outlet obstruction; results from the ICS-'BPH' Study
34. Value of the Danish Prostate Symptom Score compared to the AUA Symptom Score and pressure/flow studies in the preoperative evaluation of men with symptomatic benign prostatic hyperplasia
35. The responsiveness of the ICSmale questionnaire to outcome; evidence from the ICS-'BPH' study
36. Committee 7; symptom and quality of life assessment
37. A brief male sexual function inventory for urology
38. The International Index of Erectile Function (IIEF); a multidimensional scale for assessment of erectile dysfunction
39. Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire
40. Using ICSQoL to measure the impact of lower urinary tract symptoms on quality of life; evidence from the ICS-'BPH' study
41. Validation of a new quality of life questionnaire for benign prostatic hyperplasia